Business Combinations The Company accounted for its business combinations below under the acquisition method of accounting and measured at fair value, the identifiable assets acquired and liabilities assumed at the date of acquisition. For each business combination, the Company recorded assets and liabilities representing working capital at their historical costs, which approximate fair value given the short-term nature of the assets and liabilities. The methods used to estimate the fair value of definite-lived intangible assets are consistent with those described in Note 1, Basis of Presentation and Summary of Significant Accounting Policies, of the Companys audited consolidated financial statements included in the May 2020 Form 8-K. Acquisition of Synarc On September 3, 2019, the Company acquired 100% of the issued and outstanding equity of Synarc, Inc. (Synarc), the global site network business of Bioclinica, Inc., expanding its global footprint into China and Latin America and expanding its central nervous system offering in the United States. The purchase price was $48.6 million and was paid with cash on hand. The accounting for the acquisition is complete. The Company recorded measurement period adjustments including (i) an increase in the purchase price of $3.4 million , (ii) a net decrease in assets of $11.1 million and (iii) a net decrease in liabilities of $2.2 million , resulting in an increase of goodwill of $12.3 million . The goodwill recognized of $13.4 million was primarily the result of anticipated growth through the development of new customers, additional services to existing customers and the assembled workforce. The goodwill was assigned to a reporting unit within the Companys Clinical Development Services segment. The Company is not able to deduct goodwill for U.S. income tax purposes. The Company acquired the following definite-lived intangible assets with the acquisition of Synarc: Acquired Intangible Assets (in thousands) Weighted-Average Amortization Period (in years) Customer relationships $ 2,000 15 Know-how/processes 1,800 8 Investigator network 1,900 8 Trade names 1,400 10 Total $ 7,100 10 The following table summarizes the consideration and the fair values of identifiable assets acquired and liabilities assumed at the acquisition date (in thousands): Purchase price $ 48,635 Identifiable assets acquired: Cash and cash equivalents $ 6,003 Accounts receivable and unbilled services 18,819 Prepaid expenses and other current assets 1,590 Property and equipment 19,273 Intangible assets 7,100 Other assets 928 Operating lease right-of-use assets 1,609 Total identifiable assets acquired 55,322 Liabilities assumed: Accounts payable (2,117 ) Other accrued expenses (4,026 ) Unearned revenue (7,210 ) Long-term debt and finance lease obligations (38 ) Deferred tax liabilities (4,736 ) Other liabilities (330 ) Operating lease liabilities (1,609 ) Total liabilities assumed (20,066 ) Separately identifiable net assets acquired 35,256 Goodwill 13,379 Total net assets $ 48,635 Acquisition of Medimix On July 1, 2019, the Company acquired 100% of the issued and outstanding equity of Medimix International (Medimix), a global technology company providing real-world evidence insights and information to the pharmaceutical, diagnostic and medical device industries. The acquisition enhanced the Companys ability to leverage data to provide real-world evidence and insights for customers. The purchase price was $36.8 million , which consisted of $27.5 million of cash, $5.0 million of common stock of the Company and $4.3 million of estimated contingent consideration. Based on the fair values of identifiable assets acquired and liabilities assumed at the acquisition date, the consideration paid was allocated as follows: (i) $13.5 million to definite-lived intangible assets, (ii) $20.5 million to goodwill and (iii) $2.8 million to other net assets primarily related to net working capital. As of December 31, 2019, the Company recorded a contingent consideration liability of $9.5 million to be paid based on Medimix meeting certain performance targets through December 31, 2019. The contingent consideration was paid to the seller in July 2020. The accounting for the acquisition is complete and measurement period adjustments recorded were not material. The goodwill recognized was primarily the result of anticipated growth through the development of new customers, additional services to existing customers and the assembled workforce. The goodwill was assigned to a reporting unit within the Companys Clinical Development Services segment. The majority of goodwill is tax deductible for U.S. income tax purposes. The Company acquired the following definite-lived intangible assets with the acquisition of Medimix: Acquired Intangible Assets (in thousands) Weighted-Average Amortization Period (in years) Customer relationships $ 7,500 13 Trade names 900 10 Technology/intellectual property 5,100 8 Total $ 13,500 11 Acquisition Costs Acquisition costs for the three and nine months ended September 30, 2019 were $1.5 million and $7.1 million , respectively. There were no acquisition costs for the three and nine months ended September 30, 2020 . These costs are expensed as incurred and are included on the condensed consolidated statements of operations as a component of SG&amp;A expenses.